Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Dyadic International Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
DYAI
Nasdaq
8731
https://dyadic.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Dyadic International Inc
Dyadic to Attend Industry Events in April
- Mar 27th, 2024 12:30 pm
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
- Mar 26th, 2024 12:30 pm
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
- Mar 21st, 2024 12:30 pm
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
- Mar 14th, 2024 8:30 pm
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
- Mar 11th, 2024 1:57 pm
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
- Mar 11th, 2024 12:30 pm
Dyadic to Attend Industry Events in March
- Mar 1st, 2024 1:30 pm
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
- Feb 28th, 2024 1:30 pm
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
- Feb 23rd, 2024 7:00 am
DYAI: Catching Up With Dyadic
- Feb 20th, 2024 9:58 am
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
- Feb 13th, 2024 1:30 pm
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
- Feb 6th, 2024 1:30 pm
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
- Feb 1st, 2024 1:30 pm
Dyadic International, Inc Invites You to Join Us at The Microcap Conference
- Jan 22nd, 2024 1:00 pm
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
- Jan 2nd, 2024 1:30 pm
Dyadic Attends Investor Events in December
- Nov 30th, 2023 1:30 pm
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
- Nov 29th, 2023 1:30 pm
Shareholders in Dyadic International (NASDAQ:DYAI) are in the red if they invested three years ago
- Nov 22nd, 2023 10:55 am
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
- Nov 20th, 2023 1:30 pm
Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call Transcript
- Nov 9th, 2023 8:54 pm
Scroll